Table 2.
Summary of adverse events of any grade and of grade ≥3 adverse events
| Adverse event | Patients (n) having an adverse event (%) (N=12) | |
| All grades | Grade ≥3 | |
| Diarrhoea | 9 (75.0) | 0 |
| Asthenia | 8 (66.7) | 0 |
| Platelet count decreased | 5 (41.7) | 2 (16.7) |
| Neurotoxicity | 5 (41.7) | 0 |
| Infusion-related reaction* | 4 (33.3) | 0 |
| Nausea | 4 (33.3) | 0 |
| Neutropenia | 3 (25.0) | 2 (16.7) |
| Anaemia | 3 (25.0) | 2 (16.7) |
| Dyspnoea | 3 (25.0) | 1 (8.3) |
| Respiratory tract infection | 3 (25.0) | 1 (8.3) |
| Constipation | 3 (25.0) | 0 |
| Weight decreased | 3 (25.0) | 0 |
| Decreased appetite | 3 (25.0) | 0 |
| Alopecia | 3 (25.0) | 0 |
| Insomnia | 3 (25.0) | 0 |
| Rash | 3 (25.0) | 0 |
| Abdominal pain | 2 (16.7) | 0 |
| Abdominal pain upper | 2 (16.7) | 0 |
| Stomatitis | 2 (16.7) | 0 |
| Vomiting | 2 (16.7) | 0 |
| Fatigue | 2 (16.7) | 0 |
| Musculoskeletal pain | 2 (16.7) | 0 |
| Pain in the extremity | 2 (16.7) | 0 |
| Hypomagnesemia | 2 (16.7) | 0 |
Only adverse events reported by >10% of the patients are shown.
*Four patients had infusion-related reactions; three of which the investigator considered as related to lumretuzumab and one patient had an infusion-related reaction related to paclitaxel.